Caris Life Sciences, Inc.
Caris Life Sciences, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|
Series A Preferred Stock | - | 0 | 0 | 0 | |||||
Series B Preferred Stock | - | 0 | 0 | 0 | |||||
Series C Preferred Stock | - | 0 | 0 | 0 | |||||
Series D Preferred Stock | - | 0 | 0 | 0 | |||||
Temporary Equity Shares Authorized | - | - | - | 787 | |||||
Temporary Equity Shares Issued | - | - | - | 751 | |||||
Temporary Equity Shares Outstanding | - | - | - | 751 | |||||
Temporary Equity Liquidation Preference | - | - | - | 1,946 | |||||
Assets | |||||||||
Assets Current | |||||||||
Marketable Securities Current | 2 | 2 | 2 | 2 | |||||
Accounts Receivable Net Current | 91 | 112 | 27 | 51 | |||||
Supplies | 76 | 64 | 49 | 41 | |||||
Prepaid Expense And Other Assets Current | 24 | 22 | 21 | 19 | |||||
Assets Current | 1,014 | 998 | 854 | 833 | |||||
Property Plant And Equipment Net | 83 | 63 | 64 | 61 | |||||
Property Plant And Equipment And Finance Lease Rig… | - | 63 | - | - | |||||
Goodwill | 19 | 19 | 19 | 19 | |||||
Other Assets Noncurrent | 46 | 45 | 47 | 41 | |||||
Assets | 1,162 | 1,126 | 985 | 955 | |||||
Liabilities And Stockhold… | |||||||||
Liabilities Current | |||||||||
Accounts Payable Current | 70 | 39 | 29 | 29 | |||||
Accrued Liabilities Current | 74 | 88 | 57 | 61 | |||||
Long Term Debt Current | 0 | 0 | 0 | 0 | |||||
Liabilities Current | 144 | 127 | 86 | 90 | |||||
Long Term Debt Noncurrent | 381 | 379 | 376 | 374 | |||||
Other Liabilities Noncurrent | 44 | 42 | 44 | 38 | |||||
Liabilities | 569 | 548 | 506 | 502 | |||||
Equity | |||||||||
Preferred Stock Value | 0 | 0 | 0 | 0 | |||||
Common Stock Value | 0 | 0 | 0 | 0 | |||||
Treasury Stock Common Value | -17 | -17 | -17 | -17 | |||||
Additional Paid In Capital | 3,158 | 3,142 | 3,125 | 3,124 | |||||
Temporary Equity Number O… | |||||||||
Temporary Equity Carrying Amount Attributable To P… | - | 0 | 0 | 2,446 | |||||
Retained Earnings Accumulated Deficit | -2,549 | -2,549 | -2,631 | -2,655 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | 1 | 1 | 1 | 1 | |||||
Stockholders Equity | 593 | 577 | 478 | 453 | |||||
Liabilities And Stockholders Equity | 1,162 | 1,126 | 985 | 955 | |||||
Preferred Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Preferred Stock Shares Authorized | 100 | 100 | 100 | 100 | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Common Stock Shares Authorized | 2,800 | 2,800 | 2,800 | 2,800 | |||||
Common Stock Shares Issued | 284 | 284 | 284 | 283 | |||||
Shares Outstanding | 283 | 283 | 282 | 281 | |||||
Common Stock Other Shares Outstanding | 0 | 0 | 0 | 0 | |||||
Treasury Stock Common Shares | 2 | 2 | 2 | 2 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.53% | 14.55% | - | - | - | - | - | - | - | - | - | - |
| 2025 | - | - | - | 7.36% | -2.09% | -7.33% | -12.60% | -3.34% | -14.41% | -12.54% | 4.23% | -19.76% |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 50+ calculated metrics
Subscribe to unlock 17+ years of data and 50+ calculated metrics
Performance and Valuation Metrics
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Caris Life Sciences, Inc. (CAI) — SEC Financial Statements & Analysis
Caris Life Sciences, Inc. (CAI) is a services-medical laboratories company, incorporated in TX. Caris Life Sciences, Inc. trades on CAI: Nasdaq as: CAI. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Caris Life Sciences, Inc. reported a Gross Profit Margin of 67.40% (TTM), a Debt-to-Equity ratio of 0.96x, a Price-to-Sales (P/S) ratio of 4.91x (TTM), a Price-to-Book (P/B) ratio of 8.51 (TTM), at a market cap of $5.05B. Figures below are sourced from SEC EDGAR, as-filed.
- Gross Profit Margin TTM
- 67.40%
- Debt To Equity
- 0.96x
- P/S TTM
- 4.91x
- P/B TTM
- 8.51
- Market Cap
- $5.05B
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Caris Life Sciences, Inc. in?
Caris Life Sciences, Inc. (CAI) operates in the Services-Medical Laboratories industry.
What is CAI's market cap?
Caris Life Sciences, Inc. (CAI) has a market capitalization of $5.05B as of 2026-03-31.
What exchange does CAI trade on?
Caris Life Sciences, Inc. (CAI) trades on the CAI: Nasdaq.
Where is Caris Life Sciences, Inc. incorporated?
Caris Life Sciences, Inc. is incorporated in TX.